Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
Abstract
:1. Introduction
2. Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chi, D.S.; McCaughty, K.; Diaz, J.P.; Huh, J.; Schwabenbauer, S.; Hummer, A.J.; Venkatraman, E.S.; Aghajanian, C.; Sonoda, Y.; Abu-Rustum, N.R.; et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006, 106, 1933–1939. [Google Scholar] [CrossRef] [PubMed]
- Wilson, M.K.; Pujade-Lauraine, E.; Aoki, D.; Mirza, M.R.; Lorusso, D.; Oza, A.M.; du Bois, A.; Vergote, I.; Reuss, A.; Bacon, M. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent disease. Ann Oncol. 2017, 28, 727–732. [Google Scholar] [CrossRef] [PubMed]
- Hollis, R.L.; Churchman, M.; Gourley, C. Distinct implications of different BRCA mutations: Efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco. Targets Ther. 2017, 10, 2539–2551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Previs, R.A.; Secord, A.A. Ovarian cancer: Clinical trial breakthroughs and impact on management. Obstet. Gynecol. Clin. N. Am. 2019, 46, 67–88. [Google Scholar] [CrossRef]
- Marchetti, C.; De Leo, R.; Musella, A.; D’Indinosante, M.; Capoluongo, E.; Minucci, A.; Benedetti Panici, P.; Scambia, G.; Fagotti, A. BRCA Mutation Status to personalize management of recurrent ovarian cancer: A multicenter Study. Ann. Surg. Oncol. 2018, 25, 3701–3708. [Google Scholar] [CrossRef]
- DuBois, A.S.J.; Vergote, I.; Ferron, G.; Reuss, A.; Meier, W.; Greggi, S.; Jensen, P.T.; Selle, F.; Guyon, F.; Pomel, C.; et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGTO-ov20. J. Clin. Oncol. 2020, 38. [Google Scholar]
- Coleman, R.L.; Spirtos, N.M.; Enserro, D.; Herzog, T.J.; Sabbatini, P.; Armstrong, D.K.; Kim, J.-W.; Park, S.-Y.; Kim, B.-G.; Nam, J.-H.; et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N. Engl. J. Med. 2019, 381, 1929–1939. [Google Scholar] [CrossRef]
- Shi, T.; Zhu, J.; Feng, Y.; Tu, D.; Zhang, Y.; Zhang, P.; Jia, H.; Huang, X.; Cai, Y.; Yin, S.; et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive re- lapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021, 22, 439–449. [Google Scholar] [CrossRef]
- Guida, F.; Dioun, S.; Fagotti, A.; Melamed, A.; Grossi, A.; Scambia, G.; Wright, J.D.; Tergas, A.I. Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis. Gynecol. Oncol. 2022, 166, 181–187. [Google Scholar] [CrossRef]
- Falcone, F.; Scambia, G.; Benedetti Panici, P.; Signorelli, M.; Cormio, G.; Giorda, G.; Bogliolo, S.; Marinaccio, M.; Ghezzi, F.; Rabaiotti, E.; et al. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study. Gynecol. Oncol. 2017, 147, 66–72. [Google Scholar] [CrossRef]
- Manning-Geist, B.L.; Chi, D.S.; Long Roche, K.; Zivanovic, O.; Sonoda, Y.; Gardner, G.J.; O’Cearbhaill, R.E.; Abu-Rustum, N.R.; Leitao, M.M., Jr. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecol. Oncol. 2021, 162, 345–352. [Google Scholar] [CrossRef] [PubMed]
- Blanchard, P.; Plantade, A.; Pages, C.; Afchain, P.; Louvet, C.; Tournigand, G.; de Gramont, A. Isolated lymph node relapse of epithelial ovarian carcinoma: Outcomes and prognostic factors. Gynecol. Oncol. 2007, 104, 41–45. [Google Scholar] [CrossRef] [PubMed]
- Benedetti Panici, P.; Perniola, G.; Angioli, R.; Zullo, M.A.; Manci, N.; Palaia, I.; Bellati, F.; Plotti, F.; Calcagno, M.; Basile, S. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: Impact of surgery. Int. J. Gynecol. Cancer 2007, 17, 1245–1251. [Google Scholar] [CrossRef] [PubMed]
- Fotiou, S.; Aliki, T.; Petros, Z.; Ioanna, S.; Konstantinos, V.; Vasiliki, M.; George, C. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol. Oncol. 2009, 114, 178–182. [Google Scholar] [CrossRef]
- Ferrero, A.; Ditto, A.; Giorda, G.; Gadducci, A.; Greggi, S.; Daniele, A.; Fuso, L.; Panuccio, E.; Scaffa, C.; Raspagliesi, F.; et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study. Eur. J. Surg. Oncol. 2014, 40, 891–898. [Google Scholar] [CrossRef]
- Sapienza, L.G.; Gomes, M.J.L.; Calsavara, V.F.; Leitao, M.M., Jr.; Baiocchi, G. Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials. Gynecol. Oncol. 2017, 144, 312–317. [Google Scholar] [CrossRef] [Green Version]
- Delangle, R.; Rossard, L.; Cirier, J.; Delvallée, J.; Bendifallah, S.; Touboul, C.; Collinet, P.; Coutant, C.; Akladios, C.; Lavoué, V.; et al. Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis? Eur. J. Obstet. Gynecol. Reprod. Biol. 2020, 249, 64–69. [Google Scholar] [CrossRef]
- Kimball, R.E.; Schlaerth, J.B.; Kute, T.E.; Schlaerth, A.C.; Santoso, J.; Ballon, S.C.; Spirtos, N.M. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: Clinical and biologic significance. Am. J. Obstet. Gynecol. 1997, 176, 1319–1327. [Google Scholar] [CrossRef]
- Lee, M.; Kim, S.W.; Lee, S.H.; Paek, J.; Yim, G.W.; Kim, G.E.; Kim, S.; Kim, J.H.; Kim, Y.T.; Nam, E.J. Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer. Int. J. Gynecol. Cancer 2011, 21, 1032–1039. [Google Scholar] [CrossRef]
- Hollis, R.L.; Carmichael, J.; Meynert, A.M.; Churchman, M.; Hallas-Potts, A.; Rye, T.; MacKean, M.; Nussey, F.; Semple, C.A.; Herrington, C.S.; et al. Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. Am. J. Obstet. Gynecol. 2019, 221, 245.e1–245.e15. [Google Scholar] [CrossRef] [Green Version]
- Gallotta, V.; Conte, C.; D’Indinosante, M.; Capoluongo, E.; Minucci, A.; De Rose, A.M.; Ardito, F.; Giuliante, F.; Di Giorgio, A.; Zannoni, G.F.; et al. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. Eur. J. Surg. Oncol. 2019, 45, 2096–2102. [Google Scholar] [CrossRef]
- Gallotta, V.; Bruno, M.; Conte, C.; Giudice, M.T.; Davià, F.; Moro, F.; Zannoni, G.F.; Fagotti, A.; De Bonis, M.; Capoluongo, E.; et al. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status. Eur. J. Surg. Oncol. 2020, 46, 1327–1333. [Google Scholar] [CrossRef]
- Petrillo, M.; Fagotti, A.; Ferrandina, G.; Fanfani, F.; Costantini, B.; Vizzielli, G.; Pedone Anchora, L.; Nero, C.; Margariti, P.A.; Scambia, G. Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors. Gynecol. Oncol. 2013, 131, 36–41. [Google Scholar] [CrossRef] [PubMed]
- Tu, H.; Huang, H.; Huang, Q.D.; Li, Z.; Feng, Y.L.; Liu, J.H. Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence. Zhonghua Fu Chan Ke Za Zhi 2012, 47, 928–933. [Google Scholar]
- Pergialiotis, V.; Androutsou, A.; Papoutsi, E.; Bellos, I.; Thomakos, N.; Haidopoulos, D.; Rodolakis, A. Survival outcomes of ovarian cancer patients treated with secondary cytoreductive surgery for isolated lymph node recurrence: A systematic review of the literature. Int. J. Surg. 2019, 69, 61–66. [Google Scholar] [CrossRef]
- Conte, C.; Marchetti, C.; Loverro, M.; Giudice, M.T.; Rosati, A.; Gallotta, V.; Scambia, G.; Fagotti, A. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer. Int. J. Gynecol. Cancer 2023, 33, 137–144. [Google Scholar] [CrossRef]
- Morice, P.; Joulie, F.; Rey, A.; Atallah, D.; Camatte, S.; Pautier, P.; Thoury, A.; Lhommé, C.; Duvillard, P.; Castaigne, D. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur. J. Gynaecol. Oncol. 2004, 25, 169–174. [Google Scholar] [PubMed]
- Santillan, A.; Karam, A.K.; Li, A.J.; Karam, A.K.; Li, A.J.; Giuntoli, R.; Gardner, G.J.; Caa, I.; Karlan, B.Y.; Bristow, R.E. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol. Oncol. 2007, 104, 686–690. [Google Scholar] [CrossRef]
- Stabile, G.; Zinicola, G.; Romano, F.; Laganà, A.S.; Dal Pozzolo, C.; Ricci, G. Pelvic mass, ascites, hydrothorax: A malignant or benign condition? Meigs syndrome with high levels of CA 125. Prz Menopauzalny 2021, 20, 103–107. [Google Scholar] [CrossRef]
- Mascilini, F.; Quagliozzi, L.; Moro, F.; Moruzzi, M.C.; Gallotta, V.; Alletti, S.G.; Scambia, G.; Testa, A.C.; Fagotti, A. Role of Intraoperative Ultrasound to Extend the Application of Minimally Invasive Surgery for Treatment of Recurrent Gynecologic Cancer. J. Minim Invasive Gynecol. 2018, 25, 848–854. [Google Scholar] [CrossRef] [PubMed]
- Tinelli, G.; Cappuccio, S.; Parente, E.; Fagotti, A.; Gallotta, V.; Conte, C.; Costantini, B.; Gueli Alletti, S.; Scambia, G.; Vizzielli, G. Resectability and Vascular Management of Retroperitoneal Gynecological Malignancies: A Large Single-institution Case-Series. Anticancer Res. 2017, 37, 6899–6906. [Google Scholar] [PubMed] [Green Version]
- Bruno, M.; Legge, F.; Gentile, C.; Carone, V.; Stabile, G.; Di Leo, F.; Ludovisi, M.; Di Florio, C.; Guido, M. Risk Assessment Model for Complications in Minimally Invasive Hysterectomy: A Pilot Study. Int. J. Environ. Res. Public Health 2023, 20, 234. [Google Scholar] [CrossRef] [PubMed]
- Stabile, G.; Mordeglia, D.; Romano, F.; Carlucci, S.; Mangino, F.P.; Nappi, L.; Sorrentino, F.; De Manzini, N.; Ricci, G. Postcoital Vaginal Perforation and Evisceration in Women with No Prior Pelvic Surgery: Laparoscopic Management and Systematic Review of the Literature. Int. J. Environ. Res. Public Health 2021, 18, 9746. [Google Scholar] [CrossRef] [PubMed]
- Tew, W.P.; Lacchetti, C.; Ellis, A.; Maxian, K.; Banerjee, S.; Bookman, M.; Jones, M.B.; Lee, J.M.; Lheureux, S.; Liu, J.F.; et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J. Clin. Oncol. 2020, 38, 3468–3493. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bruno, M.; Ludovisi, M.; Ronsini, C.; Capanna, G.; Stabile, G.; Guido, M. Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina 2023, 59, 606. https://doi.org/10.3390/medicina59030606
Bruno M, Ludovisi M, Ronsini C, Capanna G, Stabile G, Guido M. Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR. Medicina. 2023; 59(3):606. https://doi.org/10.3390/medicina59030606
Chicago/Turabian StyleBruno, Matteo, Manuela Ludovisi, Carlo Ronsini, Giulia Capanna, Guglielmo Stabile, and Maurizio Guido. 2023. "Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR" Medicina 59, no. 3: 606. https://doi.org/10.3390/medicina59030606